---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000136"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:44:31.481100+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Record Q3 revenue $48.3M (+63% YoY); tightens FY23 guidance to $160-165M

## Summary
- Total revenue $48.3M, up 63% YoY and 27% QoQ; product revenue $41.7M, up 41% YoY.
- Gvoke net revenue $17.7M (+30% YoY); 58k prescriptions, 31% retail TRx glucagon share.
- Recorlev net revenue $8.1M (+$5.6M vs prior year); patients on therapy up 203%.
- Cash, cash equivalents and short-term investments $66.0M; expects cash flow breakeven in Q4 2023.
- Tightened full-year 2023 revenue guidance from $155-165M to $160-165M.

## SEC filing metadata
- accession: 0001867096-23-000136
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/0001867096-23-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/xers-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000136
- JSON: https://secwatch.observer/filing/0001867096-23-000136.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000136.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. reported the three and nine months ended September 30, 2023 results: revenue $48,320, net income Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi, EPS ($0.09) per share; ($0.36) per share. Guidance raised.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: $48,320
  - Net income: Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi
  - EPS: ($0.09) per share; ($0.36) per share
  - Guidance: raised
  - Result: reported results
  source text: 15,865 13,371 2,494 18.7 Recorlev 8,097 2,520 5,577 nm Product revenue, net 41,697 29,554 12,143 41.1 Royalty, contract and other revenue 6,623 171 6,452 nm Total revenue $ 48,320 $ 29,725 $ 18,595 62.6 nm - not meaningful Commercial Products • Gvoke® : Third quarter 2023 net revenue was $17.7 million as compared to $13.7 million in the third quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000136/0001867096-23-000136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.